Want to join the conversation?
$VRTX said the U.S. FDA accepted a supplemental New Drug Application for review for the use of its ORKAMBI drug in people with cystic fibrosis, a type of genetic disease, ages 6 to 11 who have two copies of the F508del mutation. The FDA granted the company's request for Priority Review of this sNDA, and a target review date of September 30, 2016.
The latest earnings report by $VZ shows how it is losing customers despite offering the unlimited data plans, a record for the company.
$BEBE is closing down all its stores by the end of May.
$WFC agreed to hike its payout in a class-action settlement over unauthorized accounts by $32 million to $142 million for its retail sales practices. The settlement will now include customers who were impacted as early as May 2002.